Fig. 1 · Structure

Documents & Downloads

Pexidartinib (PLX3397)

Cat. No. A15520 CAS 1029044-16-3

CSF1/Kit/FLT3 inhibitor

Pexidartinib is a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential antineoplastic activity.

In Stock

Publications for Pexidartinib

10 publications citing this product

  1. Ruoqi Yu, .et al. , Res Sq, 2026, Jul 3:rs.3.rs-10050556 PMID: 42427876
  2. Haocheng Qin, .et al. , Research (Wash D C), 2025, Sep 11:8:0861 PMID: 40948936
  3. Hannah D Mason, .et al. , Nat Immunol, 2025, Jul;26(7):1152-1167 PMID: 40555833
  4. Sarah Vanherle, .et al. , Mol Psychiatry, 2025, Oct;30(10):4512-4528 PMID: 40307424
  5. Sarah Rose Anderson, .et al. , Elife, 2022, Apr 28:11:e76564 PMID: 35481836
  6. Lu Luo, .et al. , J Neuroinflammation, 2022, Jun 11;19(1):141 PMID: 35690810
  7. Sarah R Anderson,, .et al. , bioRxiv, 2022, 01.05.475126
  8. Hannah D Mason, .et al. , JCI Insight, 2021, Oct 8;6(19):e149229 PMID: 34428178
  9. Chritica Lodder, .et al. , Acta Neuropathol Commun, 2021, Jun 8;9(1):108 PMID: 34103079
  10. Anderson SR, .et al. , Cell Rep, 2019, May 14;27(7):2002-2013.e5 PMID: 31091440

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Pexidartinib (PLX3397) is used to inhibit CSF1R-dependent microglial survival. Adult brain depletion contrasts with partial survival in developing retina, where Axl signaling supports persistence during CSF1R inhibition. These functional results do not establish exclusive kinase or cell-type selectivity. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Kit 10 nM
CSF-1R 20 nM
Flt3 160 nM

Cellular Effect

Cell Line Activity Value Description Reference
BaF3 EC50 200 nM Antiproliferative activity against mouse BaF3 cells transfected with human ETV6-CSF1R assessed as reduction in cell viability measured after 72 hrs by MTS method [PMID: 34606263]
BMDM IC50 > 10 μM Growth inhibition of CSF2-induced mouse BMDM cell assessed as inhibition of M1 like macrophage growth for 3 days by WST-8 assay [PMID: 34606263]
BMDM IC50 0.056 μM Growth inhibition of CSF1-induced mouse BMDM cell assessed as inhibition of M2 like macrophage growth incubated for 3 days by WST-8 assay [PMID: 34606263]
Caco-2 CC50 41.53 μM Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay 10.21203/rs.3.rs-23951/v1
Caco-2 IC50 5.43 μM Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging 10.21203/rs.3.rs-23951/v1
NFS-60 EC50 294 nM Antiproliferative activity against mouse NFS-60 cells transfected with human ETV6-CSF1R assessed as reduction in cell viability measured after 72 hrs by MTS method [PMID: 34606263]
NFS-60 IC50 33 nM Antiproliferative activity against CSF1-treated mouse NFS-60 cells measured after 72 hrs by resazurin method [PMID: 35961461]
NFS-60 IC50 33 nM Antiproliferative activity against CSF1-treated mouse NFS-60 cells measured after 72 hrs by resazurin method [PMID: 35961460]
RAW264.7 CC50 20.52 μM Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay [PMID: 31934767]
RAW264.7 IC50 400 nM Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced TNFalpha release measured after 24 hrs by ELISA [PMID: 31934767]
RAW264.7 IC50 430 nM Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced IL6 release measured after 24 hrs by ELISA [PMID: 31934767]
RBL-2H3 IC50 > 1000 nM Antiallergic activity against anti-DNP-IgE sensitized rat RBL-2H3 cells assessed as induction of degranulation by measuring beta-hexosaminidase release using P-nitrophenyl-N-acetyl-D-glucosamide as substrate measured after 1 hr by microplate reader [PMID: 34476950]

12 records · Scroll to view more

In Vivo Studies

In 2-month-old wild-type mice, seven days of PLX3397 at 290 mg/kg chow reduced IBA1-positive microglial counts by >90% in the hippocampus, cortex and thalamus versus vehicle chow (n = 4 per group). [1]

In postnatal retinal microglia, Axl knockout increased susceptibility to PLX3397, whereas CR3, CX3CR1 or Mer loss did not significantly lower the surviving fraction. Depletion therefore depends on the developmental and signaling context. [2]

An independent seven-day dietary study compared 660 with 75 mg/kg PLX3397 chow. Brain microglial density declined, while several heart immune-cell populations also decreased. This active-comparator design supports caution when attributing systemic PLX3397 effects solely to microglial depletion. [3]

Adult brain microglial depletion

Animal study · 2-month-old wild-type mice; hippocampus, cortex and thalamus; n = 4 per group [1]

Seven days of dietary PLX3397 reduced IBA1-positive microglia by >90% across the three regions versus vehicle chow. Microglial-marker transcripts also decreased. This design measures adult brain depletion, not kinase selectivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IBA1-positive cell bodies in a 10X field of view in hippocampus, cortex and thalamusReduction versus vehicle >90%[1]

Conditions shared by the study groups

Route
Oral, in diet
Frequency
Dietary exposure
Treatment course
7 days
Vehicle
AIN-76A standard chow
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
PLX3397 versus vehicle chow
290 mg/kg chow
Vehicle chow>90% reduction in IBA1-positive cell counts in hippocampus, cortex and thalamus.[1]
PLX3397 versus vehicle chow
Model: 2-month-old wild-type mice; n = 4 per group
Reported limits: No salt or lot information in retrieved main text.
Methods and source locations

Compound reported in the paper: Pexidartinib (PLX3397); Compound label in the paper: PLX3397

Results apply to the reported Plexxikon PLX3397 preparation and mouse model.

Results: CSF1R inhibitors dramatically reduce microglia numbers in the adult brain; Figure 2A-D and caption; Materials and Methods: Compounds, Immunostaining, Confocal microscopy

IBA1-positive cell bodies in a 10X field of view in hippocampus, cortex and thalamus: Automated IBA1 cell-body counts; n = 4 per group; Figure 2C and associated Results. Operator is author-reported, not estimated from bars. — Results: CSF1R inhibitors dramatically reduce microglia numbers in the adult brain; Figure 2A-D and caption; Materials and Methods: Compounds, Immunostaining, Confocal microscopy

PLX3397 versus vehicle chow · Results: CSF1R inhibitors dramatically reduce microglia numbers in the adult brain; Figure 2A-D and caption; Materials and Methods: Compounds, Immunostaining, Confocal microscopy

Axl-dependent survival of developmental retinal microglia

Animal study · Postnatal mouse retina across CX3CR1-GFP/+, Bax KO, CX3CR1 KO, CR3 KO, Mertk KO, Axl KO and Mertk/Axl double-KO genotypes; both sexes [2]

Axl knockout increased depletion relative to CX3CR1-GFP/+ controls, while CR3, CX3CR1 or Mertk knockout did not significantly reduce the surviving fraction. Mertk/Axl double knockout had no additive effect over Axl loss. This supports developmental-state dependence of survival after CSF1R inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Ratio of microglial density among singlets in PLX-treated retinas to genotype-matched vehicle controlsGenotype comparison of surviving fraction Axl KO: lower survival; CR3 KO, CX3CR1 KO and Mertk KO: no significant reduction versus control genotype; Mertk/Axl dKO: no additive effect over Axl KO.[2]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Daily
Treatment course
P4-P6 dosing; P7 collection
Vehicle
Corn oil and 10% DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
PLX3397 across genotypes with matched vehicle controls
0.25 mg/g body weight
Genotype-matched vehicle controls; CX3CR1-GFP/+ and Bax KO data are identified as previously published Anderson 2019 controls.Axl loss increased depletion; CR3, CX3CR1 and Mer loss did not significantly reduce the surviving fraction. Double Mertk/Axl loss was not additive.[2]
PLX3397 across genotypes with matched vehicle controls
Model: n = 17 CX3CR1-GFP/+; 5 Bax KO; 11 CX3CR1 KO; 5 CR3 KO CX3CR1-GFP/+; 9 Mertk KO; 8 Axl KO; 7 Mertk/Axl dKO; at least 2 litters per genotype
Reported limits: Caption gives n by genotype, not separately by treatment arm; preserve its meaning. Historical control data are not newly independent observations.
Methods and source locations

Compound reported in the paper: Pexidartinib (PLX3397); Compound label in the paper: PLX3397

Reported developmental retinal microglia experiment; supplier citation does not certify any current lot.

Results: Axl promotes microglial survival in the absence of CSF1R signaling; Figure 6A-C and caption; Key resources table; Methods: Animal husbandry and procedures, Mouse strains, Dissociation/FACS/flow cytometry

Ratio of microglial density among singlets in PLX-treated retinas to genotype-matched vehicle controls: Flow cytometry: CD45+ CX3CR1-GFP+ or CD45+ CD11b+ microglia/singlets. Welch ANOVA W(6,18.55) = 16.53, p < 0.0001; Dunnett T3 comparisons. Figure 6C; bars ± SEM. No exact ratios inferred. — Results: Axl promotes microglial survival in the absence of CSF1R signaling; Figure 6A-C and caption; Key resources table; Methods: Animal husbandry and procedures, Mouse strains, Dissociation/FACS/flow cytometry

PLX3397 across genotypes with matched vehicle controls · Results: Axl promotes microglial survival in the absence of CSF1R signaling; Figure 6A-C and caption; Key resources table; Methods: Animal husbandry and procedures, Mouse strains, Dissociation/FACS/flow cytometry

Brain depletion and peripheral immune effects with an active chow comparator

Animal study · Male mice, 11-13 weeks, C57BL/6J background; wild-type and CX3CR1-GFP/+ animals; brain and heart [3]

The same 7-day dietary comparison demonstrated brain microglial depletion and reductions in selected heart immune populations. The comparator contained 75 mg/kg PLX3397, so the experiment does not establish effects relative to drug-free chow.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Microglia per field of view in cortex and hippocampusDecrease versus low-dose comparator Cortex: 86.8%; hippocampus: 73.5%[3]
Recovered heart immune populationsDirection and statistical significance Reduced CD3+, NK1.1+, CD11b+Ly6G+, Ly6C-high and Ly6C-low cells; no significant difference for CD4+, CD8a+, CD19+ or MHCII+ cells.[3]

Conditions shared by the study groups

Route
Oral, in diet
Frequency
Dietary exposure
Treatment course
7 days
Vehicle
Chow
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
660 versus 75 mg/kg PLX3397 chow
660 mg/kg chow
75 mg/kg PLX3397 chow, explicitly reported in Methods Sec12Reduced brain microglial density and selected heart immune-cell populations versus the low-dose comparator; several heart lymphoid markers showed no significant difference.[3]
660 versus 75 mg/kg PLX3397 chow
Model: Male mice aged 11-13 weeks; n = 4-6 for Figure 1; n = 3 for Figure 4
Reported limits: No conversion to body-weight dose. No drug-free arm inferred from the generic Control labels in figures.
Methods and source locations

Compound reported in the paper: Pexidartinib (PLX3397); Compound label in the paper: PLX3397

Reported 7-day high-dose versus low-dose chow comparison; cannot establish systemic inertness or effects relative to drug-free controls.

Results Sec2 and Sec5; Figure 1a-j and Figure 4a-i with captions; Methods Sec11-Sec12, Sec16-Sec19

Microglia per field of view in cortex and hippocampus: CX3CR1-GFP immunohistochemistry; percentages explicitly reported in Results, not estimated. Figure 1 caption: n = 4-6; mean ± SEM; unpaired Student t test. — Results Sec2; Figure 1g-j and caption; Methods Sec11-Sec12

Recovered heart immune populations: Flow cytometry; n = 3; mean ± SEM; unpaired Student t test. Figure 4 plots cells/mL. No exact counts inferred. — Results Sec5; Figure 4a-i and caption; Methods Sec11-Sec12 and Sec18-Sec19

660 versus 75 mg/kg PLX3397 chow · Results Sec2 and Sec5; Figure 1a-j and Figure 4a-i with captions; Methods Sec11-Sec12, Sec16-Sec19

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1029044-16-3
Applications CSF1/Kit/FLT3 inhibitor
Formula C20H15ClF3N5
Molecular Weight 417.81
Synonyms PLX-3397
SMILES
FC(C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C43)C=C2)C=N1)(F)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 71 mg/mL (169.93 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
5% DMSO+45% PEG 300+5% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Elmore MR, Najafi AR, Koike MA, et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain Neuron (2014). PMID: 24742461 DOI: 10.1016/j.neuron.2014.02.040 Source material
  2. [2] Anderson SR, Roberts JM, Ghena N, et al. Neuronal apoptosis drives remodeling states of microglia and shifts in survival pathway dependence eLife (2022). PMID: 35481836 DOI: 10.7554/eLife.76564 Source material
  3. [3] Okojie AK, Uweru JO, Coburn MA, et al. Distinguishing the effects of systemic CSF1R inhibition by PLX3397 on microglia and peripheral immune cells Journal of Neuroinflammation (2023). PMID: 37865779 DOI: 10.1186/s12974-023-02924-5 Source material

Publications

10 publications citing this product

  1. Ruoqi Yu, .et al. , Res Sq, 2026, Jul 3:rs.3.rs-10050556 PMID: 42427876
  2. Haocheng Qin, .et al. , Research (Wash D C), 2025, Sep 11:8:0861 PMID: 40948936
  3. Hannah D Mason, .et al. , Nat Immunol, 2025, Jul;26(7):1152-1167 PMID: 40555833
  4. Sarah Vanherle, .et al. , Mol Psychiatry, 2025, Oct;30(10):4512-4528 PMID: 40307424
  5. Sarah Rose Anderson, .et al. , Elife, 2022, Apr 28:11:e76564 PMID: 35481836
  6. Lu Luo, .et al. , J Neuroinflammation, 2022, Jun 11;19(1):141 PMID: 35690810
  7. Sarah R Anderson,, .et al. , bioRxiv, 2022, 01.05.475126
  8. Hannah D Mason, .et al. , JCI Insight, 2021, Oct 8;6(19):e149229 PMID: 34428178
  9. Chritica Lodder, .et al. , Acta Neuropathol Commun, 2021, Jun 8;9(1):108 PMID: 34103079
  10. Anderson SR, .et al. , Cell Rep, 2019, May 14;27(7):2002-2013.e5 PMID: 31091440

Added to your cart

View Cart Checkout
Loading...